26 USC § 45C - Clinical testing expenses for certain drugs for rare diseases or conditions
(a)
General rule
For purposes of section
38, the credit determined under this section for the taxable year is an amount equal to 50 percent of the qualified clinical testing expenses for the taxable year.
(b)
Qualified clinical testing expenses
For purposes of this section—
(1)
Qualified clinical testing expenses
(A)
In general
Except as otherwise provided in this paragraph, the term “qualified clinical testing expenses” means the amounts which are paid or incurred by the taxpayer during the taxable year which would be described in subsection (b) ofsection
41 if such subsection were applied with the modifications set forth in subparagraph (B).
(B)
Modifications
For purposes of subparagraph (A), subsection (b) ofsection
41 shall be applied—
(C)
Exclusion for amounts funded by grants, etc.
The term “qualified clinical testing expenses” shall not include any amount to the extent such amount is funded by any grant, contract, or otherwise by another person (or any governmental entity).
(D)
Special rule
For purposes of this paragraph, section
41 shall be deemed to remain in effect for periods after June 30, 1995, and before July 1, 1996, and periods after December 31, 2013.
(2)
Clinical testing
(A)
In general
The term “clinical testing” means any human clinical testing—
(i)
which is carried out under an exemption for a drug being tested for a rare disease or condition under section 505(i) of the Federal Food, Drug, and Cosmetic Act (or regulations issued under such section),
(ii)
which occurs—
(II)
before the date on which an application with respect to such drug is approved under section 505(b) of such Act or, if the drug is a biological product, before the date on which a license for such drug is issued under section 351 of the Public Health Service Act;
[1]
and
(iii)
which is conducted by or on behalf of the taxpayer to whom the designation under such section
526 applies.
(B)
Testing must be related to use for rare disease or condition
Human clinical testing shall be taken into account under subparagraph (A) only to the extent such testing is related to the use of a drug for the rare disease or condition for which it was designated under section 526 of the Federal Food, Drug, and Cosmetic Act.
(c)
Coordination with credit for increasing research expenditures
(1)
In general
Except as provided in paragraph (2), any qualified clinical testing expenses for a taxable year to which an election under this section applies shall not be taken into account for purposes of determining the credit allowable under section
41 for such taxable year.
(d)
Definition and special rules
(1)
Rare disease or condition
For purposes of this section, the term “rare disease or condition” means any disease or condition which—
(B)
affects more than 200,000 persons in the United States but for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the United States of such drug.
Determinations under the preceding sentence with respect to any drug shall be made on the basis of the facts and circumstances as of the date such drug is designated under section 526 of the Federal Food, Drug, and Cosmetic Act.
(2)
Special limitations on foreign testing
(A)
In general
No credit shall be allowed under this section with respect to any clinical testing conducted outside the United States unless—
(B)
Special limitation for corporations to which section
936 applies
No credit shall be allowed under this section with respect to any clinical testing conducted by a corporation to which an election under section
936 applies.
[1] So in original. The semicolon probably should be a comma.
(a)
General rule
For purposes of section
38, the credit determined under this section for the taxable year is an amount equal to 50 percent of the qualified clinical testing expenses for the taxable year.
(b)
Qualified clinical testing expenses
For purposes of this section—
(1)
Qualified clinical testing expenses
(A)
In general
Except as otherwise provided in this paragraph, the term “qualified clinical testing expenses” means the amounts which are paid or incurred by the taxpayer during the taxable year which would be described in subsection (b) ofsection
41 if such subsection were applied with the modifications set forth in subparagraph (B).
(B)
Modifications
For purposes of subparagraph (A), subsection (b) ofsection
41 shall be applied—
(C)
Exclusion for amounts funded by grants, etc.
The term “qualified clinical testing expenses” shall not include any amount to the extent such amount is funded by any grant, contract, or otherwise by another person (or any governmental entity).
(D)
Special rule
For purposes of this paragraph, section
41 shall be deemed to remain in effect for periods after June 30, 1995, and before July 1, 1996, and periods after December 31, 2011.
(2)
Clinical testing
(A)
In general
The term “clinical testing” means any human clinical testing—
(i)
which is carried out under an exemption for a drug being tested for a rare disease or condition under section 505(i) of the Federal Food, Drug, and Cosmetic Act (or regulations issued under such section),
(ii)
which occurs—
(II)
before the date on which an application with respect to such drug is approved under section 505(b) of such Act or, if the drug is a biological product, before the date on which a license for such drug is issued under section 351 of the Public Health Service Act;
[1]
and
(iii)
which is conducted by or on behalf of the taxpayer to whom the designation under such section
526 applies.
(B)
Testing must be related to use for rare disease or condition
Human clinical testing shall be taken into account under subparagraph (A) only to the extent such testing is related to the use of a drug for the rare disease or condition for which it was designated under section 526 of the Federal Food, Drug, and Cosmetic Act.
(c)
Coordination with credit for increasing research expenditures
(1)
In general
Except as provided in paragraph (2), any qualified clinical testing expenses for a taxable year to which an election under this section applies shall not be taken into account for purposes of determining the credit allowable under section
41 for such taxable year.
(d)
Definition and special rules
(1)
Rare disease or condition
For purposes of this section, the term “rare disease or condition” means any disease or condition which—
(B)
affects more than 200,000 persons in the United States but for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the United States of such drug.
Determinations under the preceding sentence with respect to any drug shall be made on the basis of the facts and circumstances as of the date such drug is designated under section 526 of the Federal Food, Drug, and Cosmetic Act.
(2)
Special limitations on foreign testing
(A)
In general
No credit shall be allowed under this section with respect to any clinical testing conducted outside the United States unless—
(B)
Special limitation for corporations to which section
936 applies
No credit shall be allowed under this section with respect to any clinical testing conducted by a corporation to which an election under section
936 applies.
[1] So in original. The semicolon probably should be a comma.
Source
(Added Pub. L. 97–414, § 4(a),Jan. 4, 1983, 96 Stat. 2053, § 44H; renumbered § 28 and amended Pub. L. 98–369, div. A, title IV, §§ 471(c),
474
(g), title VI, § 612(e)(1),July 18, 1984, 98 Stat. 826, 831, 912; Pub. L. 99–514, title II, §§ 231(d)(3)(A),
232, title VII, § 701(c)(2), title XII, § 1275(c)(4), title XVIII, § 1879(b)(1), (2),Oct. 22, 1986, 100 Stat. 2178, 2180, 2340, 2599, 2905; Pub. L. 100–647, title I, § 1018(q)(1), title IV, § 4008(c)(1),Nov. 10, 1988, 102 Stat. 3585, 3653; Pub. L. 101–239, title VII, § 7110(a)(3),Dec. 19, 1989, 103 Stat. 2323; Pub. L. 101–508, title XI, §§ 11402(b)(2),
11411,Nov. 5, 1990, 104 Stat. 1388–473, 1388–479; Pub. L. 102–227, title I, §§ 102(b),
111
(a),Dec. 11, 1991, 105 Stat. 1686, 1688; Pub. L. 103–66, title XIII, § 13111(a)(2), (b),Aug. 10, 1993, 107 Stat. 420; renumbered § 45C and amended Pub. L. 104–188, title I, §§ 1204(e),
1205(a)(1), (b), (d)(1), (2),Aug. 20, 1996, 110 Stat. 1775, 1776; Pub. L. 105–34, title VI, §§ 601(b)(2),
604(a),Aug. 5, 1997, 111 Stat. 862, 863; Pub. L. 105–115, title I, § 125(b)(2)(O),Nov. 21, 1997, 111 Stat. 2326; Pub. L. 105–277, div. J, title I, § 1001(b),Oct. 21, 1998, 112 Stat. 2681–888; Pub. L. 106–170, title V, § 502(a)(2),Dec. 17, 1999, 113 Stat. 1919; Pub. L. 108–311, title III, § 301(a)(2),Oct. 4, 2004, 118 Stat. 1178; Pub. L. 109–432, div. A, title I, § 104(a)(2),Dec. 20, 2006, 120 Stat. 2934; Pub. L. 110–343, div. C, title III, § 301(a)(2),Oct. 3, 2008, 122 Stat. 3865; Pub. L. 111–312, title VII, § 731(b),Dec. 17, 2010, 124 Stat. 3317.)
References in Text
Sections 505(b), (i) and 526 of the Federal Food, Drug, and Cosmetic Act, referred to in subsecs. (b)(2)(A) and (d)(1), (2)(A)(ii), are classified to sections
355
(b), (i) and
360bb, respectively, of Title
21, Food and Drugs.
Section 351 of the Public Health Service Act, referred to in subsec. (b)(2)(A)(ii)(II), is classified to section
262 of Title
42, The Public Health and Welfare.
Amendments
2010—Subsec. (b)(1)(D). Pub. L. 111–312substituted “December 31, 2011” for “December 31, 2009”.
2008—Subsec. (b)(1)(D). Pub. L. 110–343substituted “December 31, 2009” for “December 31, 2007”.
2006—Subsec. (b)(1)(D). Pub. L. 109–432substituted “2007” for “2005”.
2004—Subsec. (b)(1)(D). Pub. L. 108–311substituted “December 31, 2005” for “June 30, 2004”.
1999—Subsec. (b)(1)(D). Pub. L. 106–170substituted “June 30, 2004” for “June 30, 1999”.
1998—Subsec. (b)(1)(D). Pub. L. 105–277substituted “June 30, 1999” for “June 30, 1998”.
1997—Subsec. (b)(1)(D). Pub. L. 105–34, § 601(b)(2), substituted “June 30, 1998” for “May 31, 1997”.
Subsec. (b)(2)(A)(ii)(II). Pub. L. 105–115struck out “or 507” after “505(b)”.
Subsec. (e). Pub. L. 105–34, § 604(a), struck out subsec. (e) which read as follows:
“(e) Termination.—This section shall not apply to any amount paid or incurred—
“(1) after December 31, 1994, and before July 1, 1996, or
“(2) after May 31, 1997.”
1996—Pub. L. 104–188, § 1205(a)(1), renumbered section
28 of this title as this section.
Subsec. (a). Pub. L. 104–188, § 1205(d)(1), substituted “For purposes of section
38, the credit determined under this section for the taxable year is” for “There shall be allowed as a credit against the tax imposed by this chapter for the taxable year”.
Subsec. (b)(1)(D). Pub. L. 104–188, § 1204(e), inserted “, and before July 1, 1996, and periods after May 31, 1997” after “June 30, 1995”.
Subsec. (d)(2) to (5). Pub. L. 104–188, § 1205(d)(2), redesignated pars. (3) to (5) as (2) to (4), respectively, and struck out former par. (2) which read as follows: “Limitation based on amount of tax.—The credit allowed by this section for any taxable year shall not exceed the excess (if any) of—
“(A) the regular tax (reduced by the sum of the credits allowable under subpart A and section
27), over
“(B) the tentative minimum tax for the taxable year.”
Subsec. (e). Pub. L. 104–188, § 1205(b), amended subsec. (e) generally. Prior to amendment, subsec. (e) read as follows: “Termination.—This section shall not apply to any amount paid or incurred after December 31, 1994.”
1993—Subsec. (b)(1)(D). Pub. L. 103–66, § 13111(a)(2), substituted “June 30, 1995” for “June 30, 1992”.
Subsec. (e). Pub. L. 103–66, § 13111(b), substituted “December 31, 1994” for “June 30, 1992”.
1991—Subsec. (b)(1)(D). Pub. L. 102–227, § 102(b), substituted “June 30, 1992” for “December 31, 1991”.
Subsec. (e). Pub. L. 102–227, § 111(a), substituted “June 30, 1992” for “December 31, 1991”.
1990—Subsec. (b)(1)(D). Pub. L. 101–508, § 11402(b)(2), substituted “December 31, 1991” for “December 31, 1990”.
Subsec. (e). Pub. L. 101–508, § 11411, substituted “December 31, 1991” for “December 31, 1990”.
1989—Subsec. (b)(1)(D). Pub. L. 101–239substituted “1990” for “1989”.
1988—Subsec. (b)(1)(D). Pub. L. 100–647, § 4008(c)(1), substituted “1989” for “1988”.
Subsec. (b)(2)(A)(ii)(II). Pub. L. 100–647, § 1018(q)(1), amended subcl. (II) generally. Prior to amendment, subcl. (II) read as follows: “before the date on which an application with respect to such drug is approved under section 505(b) of such Act or, if the drug is a biological product, before the date on which a license for such drug is issued under section 351 of the Public Health Services Act, and”.
1986—Subsec. (b)(1). Pub. L. 99–514, § 231(d)(3)(A)(i), (iv), substituted “41” for “30” in subpars. (A), (B), and (D), and substituted “1988” for “1985” in subpar. (D).
Subsec. (b)(2)(A)(ii)(I). Pub. L. 99–514, § 1879(b)(1)(A), substituted “the date such drug” for “the date of such drug”.
Subsec. (b)(2)(A)(ii)(II). Pub. L. 99–514, § 1879(b)(1)(B), inserted “or, if the drug is a biological product, before the date on which a license for such drug is issued under section 351 of the Public Health Services Act”.
Subsec. (c). Pub. L. 99–514, § 231(d)(3)(A)(i), (ii), substituted “41” for “30” in pars. (1) and (2) and “41(b)” for “30(b)” in par. (2).
Subsec. (d)(1). Pub. L. 99–514, § 1879(b)(2), amended par. (1) generally. Prior to amendment, par. (1) read as follows: “For purposes of this section, the term ‘rare disease or condition’ means any disease or condition which occurs so infrequently in the United States that there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the United States of such drug. Determinations under the preceding sentence with respect to any drug shall be made on the basis of the facts and circumstances as of the date such drug is designated under section 526 of the Federal Food, Drug, and Cosmetic Act.”
Subsec. (d)(2). Pub. L. 99–514, § 701(c)(2), amended par. (2) generally. Prior to amendment, par. (2) read as follows: “The credit allowed by this section for any taxable year shall not exceed the taxpayer’s tax liability for the taxable year (as defined in section
26
(b)), reduced by the sum of the credits allowable under subpart A and section
27.”
Subsec. (d)(3)(B). Pub. L. 99–514, § 1275(c)(4), struck out “934(b) or” before “936” in heading and amended text generally. Prior to amendment, text read as follows: “No credit shall be allowed under this section with respect to any clinical testing conducted by a corporation to which section
934
(b) applies or to which an election under section
936 applies.”
Subsec. (d)(4). Pub. L. 99–514, § 231(d)(3)(A)(iii), substituted “section
41
(f)” for “section
30
(f)”.
Subsec. (e). Pub. L. 99–514, § 232, substituted “1990” for “1987”.
1984—Pub. L. 98–369, § 471(c), renumbered section
44H of this title as this section.
Subsec. (b)(1)(A), (B), (D). Pub. L. 98–369, § 474(g)(1)(A), substituted “section
30” for “section
44F”.
Subsec. (c)(2). Pub. L. 98–369, § 474(g)(1)(A), (B), substituted “section
30” for “section
44F” and “section
30
(b)” for “section
44F
(b)”.
Pub. L. 98–369, § 474(g)(2), amended par. (2) generally, substituting “shall not exceed the taxpayer’s tax liability for the taxable year (as defined in section
25
(b), reduced by the sum of the credits allowable under subpart A and section
27” for “shall not exceed the amount of the tax imposed by this chapter for the taxable year reduced by the sum of the credits allowable under a section of this subpart having a lower number or letter designation than this section, other than the credits allowable by sections
31,
39, and
43. For purposes of the preceding sentence, the term ‘tax imposed by this chapter’ shall not include any tax treated as not imposed by this chapter under the last sentence of section
53
(a)”.
Effective Date of 2010 Amendment
Amendment by Pub. L. 111–312applicable to amounts paid or incurred after Dec. 31, 2009, see section 731(c) ofPub. L. 111–312, set out as a note under section
41 of this title.
Effective Date of 2008 Amendment
Amendment by Pub. L. 110–343applicable to amounts paid or incurred after Dec. 31, 2007, see section 301(e)(2) ofPub. L. 110–343, set out as a note under section
41 of this title.
Effective Date of 2006 Amendment
Amendment by Pub. L. 109–432applicable to amounts paid or incurred after Dec. 31, 2005, see section 104(a)(3) ofPub. L. 109–432, set out as a note under section
41 of this title.
Effective Date of 2004 Amendment
Amendment by Pub. L. 108–311applicable to amounts paid or incurred after June 30, 2004, see section 301(b) ofPub. L. 108–311, set out as a note under section
41 of this title.
Effective Date of 1999 Amendment
Amendment by Pub. L. 106–170applicable to amounts paid or incurred after June 30, 1999, see section 502(a)(3) ofPub. L. 106–170, set out as a note under section
41 of this title.
Effective Date of 1998 Amendment
Amendment by Pub. L. 105–277applicable to amounts paid or incurred after June 30, 1998, see section 1001(c) ofPub. L. 105–277, set out as a note under section
41 of this title.
Effective Date of 1997 Amendment
Amendment by section 601(b)(2) ofPub. L. 105–34applicable to amounts paid or incurred after May 31, 1997, see section 601(c) ofPub. L. 105–34, set out as a note under section
41 of this title.
Section 604(b) ofPub. L. 105–34provided that: “The amendment made by subsection (a) [amending this section] shall apply to amounts paid or incurred after May 31, 1997.”
Effective Date of 1996 Amendment
Amendment by section 1204(e) ofPub. L. 104–188applicable to taxable years ending after June 30, 1996, and not to be taken into account under section
6654 or
6655 of this title in determining amount of any installment required to be paid for a taxable year beginning in 1997, see section 1204(f) ofPub. L. 104–188, set out as a note under section
41 of this title.
Amendment by section 1205(a)(1), (b), (d)(1), (2) ofPub. L. 104–188applicable to amounts paid or incurred in taxable years ending after June 30, 1996, see section 1205(e) ofPub. L. 104–188, set out as a note under section
45K of this title.
Effective Date of 1993 Amendment
Section 13111(c) ofPub. L. 103–66provided that: “The amendments made by this section [amending this section and section
41 of this title] shall apply to taxable years ending after June 30, 1992.”
Effective Date of 1991 Amendment
Section 102(c) ofPub. L. 102–227provided that: “The amendments made by this section [amending this section and section
41 of this title] shall apply to taxable years ending after December 31, 1991.”
Section 111(b) ofPub. L. 102–227provided that: “The amendment made by this section [amending this section] shall apply to taxable years ending after December 31, 1991.”
Effective Date of 1990 Amendment
Section 11402(c) ofPub. L. 101–508provided that: “The amendments made by this section [amending this section and section
41 of this title and repealing provisions set out as a note under section
41 of this title] shall apply to taxable years beginning after December 31, 1989.”
Effective Date of 1988 Amendment
Amendment by section 1018(q)(1) ofPub. L. 100–647effective, except as otherwise provided, as if included in the provision of the Tax Reform Act of 1986, Pub. L. 99–514, to which such amendment relates, see section 1019(a) ofPub. L. 100–647, set out as a note under section
1 of this title.
Amendment by section 4008(c)(1) ofPub. L. 100–647applicable to taxable years beginning after Dec. 31, 1988, see section 4008(d) ofPub. L. 100–647, set out as a note under section
41 of this title.
Effective Date of 1986 Amendment
Amendment by section 231(d)(3)(A) ofPub. L. 99–514applicable to taxable years beginning after Dec. 31, 1985, see section 231(g) ofPub. L. 99–514, set out as a note under section
41 of this title.
Amendment by section 701(c)(2) ofPub. L. 99–514applicable to taxable years beginning after Dec. 31, 1986, with certain exceptions and qualifications, see section 701(f) ofPub. L. 99–514, set out as an Effective Date note under section
55 of this title.
Amendment by section 1275(c)(4) ofPub. L. 99–514applicable to taxable years beginning after Dec. 31, 1986, with certain exceptions and qualifications, see section 1277 ofPub. L. 99–514, set out as a note under section
931 of this title.
Section 1879(b)(3) ofPub. L. 99–514provided that: “The amendments made by this subsection [amending this section] shall apply to amounts paid or incurred after December 31, 1982, in taxable years ending after such date.”
Effective Date of 1984 Amendment
Amendment by section 474(g) ofPub. L. 98–369applicable to taxable years beginning after Dec. 31, 1983, and to carrybacks from such years, see section 475(a) ofPub. L. 98–369, set out as a note under section
21 of this title.
Amendment by section 612(e)(1) ofPub. L. 98–369, applicable to interest paid or accrued after December 31, 1984, on indebtedness incurred after December 31, 1984, see section 612(g) ofPub. L. 98–369, set out as an Effective Date note under section
25 of this title.
Effective Date
Section 4(d) ofPub. L. 97–414provided that: “The amendments made by this section [enacting this section and amending sections
280C and
6096 of this title] shall apply to amounts paid or incurred after December 31, 1982, in taxable years ending after such date.”
Applicability of Certain Amendments by Public Law 99–514 in Relation to Treaty Obligations of United States
For applicability of amendment by section 701(c)(2) ofPub. L. 99–514notwithstanding any treaty obligation of the United States in effect on Oct. 22, 1986, with provision that for such purposes any amendment by title I of Pub. L. 100–647be treated as if it had been included in the provision of Pub. L. 99–514to which such amendment relates, see section 1012(aa)(2), (4) ofPub. L. 100–647, set out as a note under section
861 of this title.
Plan Amendments Not Required Until January 1, 1989
For provisions directing that if any amendments made by subtitle A or subtitle C of title XI [§§ 1101–1147 and
1171–1177] or title XVIII [§§ 1800–1899A] of Pub. L. 99–514require an amendment to any plan, such plan amendment shall not be required to be made before the first plan year beginning on or after Jan. 1, 1989, see section 1140 ofPub. L. 99–514, as amended, set out as a note under section
401 of this title.
The table below lists the classification updates, since Jan. 3, 2012, for this section. Updates to a broader range of sections may be found at the update page for containing chapter, title, etc.
The most recent Classification Table update that we have noticed was Thursday, March 14, 2013
An empty table indicates that we see no relevant changes listed in the classification tables. If you suspect that our system may be missing something, please double-check with the Office of the Law Revision Counsel.
| 26 USC | Description of Change | Session Year | Public Law | Statutes at Large |
|---|---|---|---|---|
| § 45C | 2012 | 112-240 [Sec.] 301(a)(2) | 126 Stat. 2326 |
LII has no control over and does not endorse any external Internet site that contains links to or references LII.